Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group

The international, randomized phase 3 HD15 trial established 6xeBEACOPP as standard therapy for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) within the German Hodgkin Study Group (GHSG). We performed a follow-up analysis to assess long-term efficacy and safety of this approach....

Descripción completa

Detalles Bibliográficos
Autores principales: Engert, Andreas, Goergen, Helen, Markova, Jana, Pabst, Thomas, Meissner, Julia, Zijlstra, Josée M., Král, Zdenek, Eichenauer, Dennis A., Soekler, Martin, Greil, Richard, Kreissl, Stefanie, Scheuvens, Ruth, Eich, Hans, Kobe, Carsten, Dietlein, Markus, Stein, Harald, Fuchs, Michael, Diehl, Volker, Borchmann, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745969/
https://www.ncbi.nlm.nih.gov/pubmed/31723734
http://dx.doi.org/10.1097/HS9.0000000000000005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745969/
https://www.ncbi.nlm.nih.gov/pubmed/31723734
http://dx.doi.org/10.1097/HS9.0000000000000005

Ejemplares similares